Posted by Michael Wonder on 17 Jan 2025
Senaparib approved by NMPA for first-line maintenance therapy in ovarian cancer
16 January 2025 - Impact Therapeutics is pleased to announce that senaparib capsules has received marketing authorisation in China from National Medical Products Administration as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
Senaparib, discovered and developed by IMPACT, is a potent and novel PARP 1/2 inhibitor. Its distinctive molecular structure provides it with high in vitro and in vivo activity, exceptional target selectivity and wide safety window. The approval is based on FLAMES study.
